Established in 1992, the 340B Drug Pricing Program has many nuances and applications to different situations. Fundamentally, it requires pharmaceutical manufacturers to sell outpatient drugs at significantly reduced prices to eligible safety-net hospitals and clinics, requires pharmaceutical manufacturers to provide up-front discounts and pharmaceutical manufacturers participating in Medicaid agree to provide outpatient drugs to covered entities at significantly reduced prices. The conditions of participation and compliance are not simple.
The goal of this webinar is to explain key facets of the 340B Program and delve into recent opinions from the U.S. Courts of Appeals for the Ninth Circuit and the Fourth Circuit.
Negotiations impact almost every aspect of your life when you have to deal with other people, be the...
Many solo and small law firms assume AI governance is something only large firms need. It is not. AI...
Explore the transformative potential of generative AI in modern litigation. “Generative AI for...
This program will address the ethical obligations of Lawyer Advocates representing clients in mediat...
This course will provide a detailed overview of the Medicare Secondary Payer act as well as provide ...
This interactive course is designed to equip legal professionals with the knowledge, tools, and stra...
Learn about the latest trends in Federal Suspension and Debarments. This presentation will assist yo...
Contracting with the Federal Government is not like a business deal between two companies or a contr...
Part 2 - This program will continue the discussion from Part 1 focusing specifically on cross?examin...
Effective data privacy and artificial intelligence governance programs do not happen by accident. Th...